Immuron Limited (IMRN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Immuron Limited (IMRN) Healthcare & Pipeline Overview

Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing polyclonal antibodies for gut health and infectious diseases. Its portfolio includes OTC products like Travelan and a clinical pipeline addressing traveler's diarrhea, Clostridium difficile, and military-relevant infections through strategic collaborations.

What Is the Investment Thesis for IMRN?

Immuron Limited (IMRN) presents an investment profile centered on its biopharmaceutical pipeline and existing commercial products, Travelan and Protectyn, within the growing global travel and gut health markets. With a market capitalization of $10.5M, the company operates with a gross margin of 63.7%, indicating strong product-level profitability, despite a negative profit margin of -62.1% and a negative ROE of -39.7%, typical for a company heavily invested in R&D. The ongoing Phase III clinical trials for IMM-124E, targeting traveler's diarrhea and potential anti-viral activity against SARS-CoV-2, represent a significant near-term catalyst. Additionally, the clinical development of IMM-529 for recurrent Clostridium difficile infections and strategic collaborations with military research centers for Campylobacter, ETEC, and shigellosis therapeutics underscore its long-term growth potential in specialized infectious disease markets. However, a debt-to-equity ratio of 1.56 and its micro-cap status with inherent liquidity and funding risks necessitate close monitoring of clinical trial outcomes, regulatory approvals, and future financing activities.

Based on FMP financials and quantitative analysis

IMRN Key Highlights

Market Capitalization of $10.5M reflects its status as a micro-cap biopharmaceutical company.

• Gross Margin of 63.7% demonstrates strong product-level profitability for its commercialized hyperimmune products.
• Profit Margin of -62.1% and Return on Equity (ROE) of -39.7% indicate significant ongoing investment in research and development, common for clinical-stage biopharma firms.
• Debt-to-Equity ratio of 1.56 suggests a notable reliance on debt financing relative to equity.
• Beta of 0.49 indicates lower volatility compared to the broader market, potentially due to its specific niche and development-stage nature.

Who Are IMRN's Competitors?

IMRN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are IMRN's Key Strengths?

Specialized focus on polyclonal antibodies, a unique therapeutic approach.

• Existing commercial products (Travelan, Protectyn) provide current revenue streams.
• Diverse clinical pipeline addressing significant unmet medical needs (e.g., C. difficile, anti-viral).
• Strategic collaborations with reputable research institutions like Naval Medical Research Center and Walter Reed Army Institute of Research.
• Gross margin of 63.7% indicates strong product-level profitability for current offerings.

What Are IMRN's Weaknesses?

Negative profit margin (-62.1%) and ROE (-39.7%) reflect significant R&D costs and lack of overall profitability.

• High Debt-to-Equity ratio (1.56) suggests reliance on debt financing.
• Micro-cap status ($10.5M market cap) implies inherent liquidity and funding risks.
• Small employee base (7 employees) may limit operational scale and capacity.
• High dependence on successful clinical trial outcomes and regulatory approvals for pipeline assets.

What Could Drive IMRN Stock Higher?

IMRN catalyst: **IMM-124E Phase III Clinical Trial Results:** Positive outcomes from the ongoing Phase III clinical trials for IMM-124E, targeting traveler's diarrhea and potential anti-viral activity against SARS-CoV-2, are anticipated.

• Successful trial completion could lead to regulatory filings and significantly expand the product's market potential.
• **IMM-529 Clinical Development Progress:** Continued advancement and positive data readouts from the clinical development program for IMM-529, aimed at treating recurrent Clostridium difficile infections, will be a key catalyst. Progression through clinical phases could de-risk the asset and attract further investment interest.
• **Strategic Collaboration Milestones:** Achievement of specific research milestones or positive preclinical/clinical data from collaborations with the Naval Medical Research Center (Campylobacter/ETEC) and the Walter Reed Army Institute of Research (shigellosis) could provide validation and potential for future development funding or contracts.

What Are the Key Risks for IMRN?

Financial-distress signal — its Altman Z-Score of -4.73 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-43.9%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 4 reported quarters.
• **Clinical Trial Failures:** The primary risk for Immuron Limited is the potential for its pipeline candidates, particularly IMM-124E and IMM-529, to fail in clinical trials or not achieve desired efficacy and safety endpoints. Such failures would significantly impact the company's future growth prospects and valuation.
• **Funding and Liquidity Risks:** As a micro-cap company with a negative profit margin and ROE, Immuron faces ongoing funding challenges. The need for capital to sustain R&D and commercialization efforts could lead to dilutive equity financing or increased debt, impacting shareholder value.
• **Regulatory Approval Delays:** Even with successful clinical trials, Immuron's products are subject to stringent regulatory approval processes. Delays or unexpected requirements from regulatory bodies (e.g., FDA, TGA) could postpone market entry and revenue generation, increasing development costs.
• **Intense Competition:** The biotechnology and pharmaceutical sectors are highly competitive. Immuron's products and pipeline candidates face competition from established players with greater financial resources, broader product portfolios, and more extensive marketing capabilities, potentially limiting market share and pricing power.
• **Intellectual Property Challenges:** The company's success relies on its ability to protect its proprietary polyclonal antibody technology and product formulations. Challenges to intellectual property rights, such as patent infringements or expiration, could erode its competitive advantage and long-term profitability.

What Are the Growth Opportunities for IMRN?

• **Expansion of Travelan in the Global Travel Market:** The increasing global travel market presents a significant growth opportunity for Immuron's flagship product, Travelan. As international travel resumes and expands, the demand for effective preventative solutions against traveler's diarrhea is expected to rise. Travelan, an over-the-counter medicine, is well-positioned to capitalize on this trend, offering a convenient and accessible option for travelers. The global travel health market is projected to grow, with preventative measures being a key segment. Immuron can leverage its existing commercial presence and potential marketing initiatives to capture a larger share of this market, enhancing revenue streams from its hyperimmune products segment.
• **Successful Development and Commercialization of IMM-124E:** The advanced formulation of Travelan, IMM-124E, currently undergoing Phase III clinical trials, represents a substantial growth driver. This pipeline candidate is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. A successful outcome in Phase III trials and subsequent regulatory approval could significantly expand the addressable market for this product, positioning Immuron in both the travel health and broader anti-viral therapeutic spaces. The dual-purpose nature of IMM-124E could unlock substantial revenue potential and provide a competitive advantage in a post-pandemic world.
• **Advancement of IMM-529 for Recurrent Clostridium difficile Infections:** Immuron's pipeline candidate, IMM-529, in clinical development for treating recurrent Clostridium difficile infections, targets a critical unmet medical need. Clostridium difficile infection (CDI) is a serious and often recurrent condition, particularly challenging in healthcare settings. The market for CDI therapeutics is substantial, driven by an aging population and increasing antibiotic resistance. Successful progression through clinical development and eventual commercialization of IMM-529 could establish Immuron as a key player in the infectious disease therapeutic market, offering a novel approach to a persistent health challenge and diversifying its product portfolio beyond traveler's health.
• **Leveraging Strategic Collaboration with Naval Medical Research Center:** The research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections offers a specialized growth opportunity. These infections are significant health threats, particularly in military and developing world contexts, where conventional treatments may be limited or ineffective. Success in this collaboration could lead to the development of novel therapeutics with potential for government contracts, military procurement, and broader humanitarian applications. This partnership provides access to specialized research capabilities and a defined target population, potentially accelerating product development and market entry in niche but high-impact areas.
• **Exploiting Collaboration with Walter Reed Army Institute of Research for Shigellosis:** Immuron's collaboration with the Walter Reed Army Institute of Research, focused on creating an oral therapeutic for shigellosis, represents another strategic growth avenue in the infectious disease space. Shigellosis is a highly contagious bacterial infection causing severe diarrheal disease, prevalent in regions with poor sanitation and a concern for military personnel deployed globally. Developing an effective oral therapeutic could address a significant public health challenge and offer a valuable product for military and international aid organizations. This collaboration underscores Immuron's commitment to addressing critical global health threats and could open doors to specialized procurement markets and further research funding.

What Are IMRN's Competitive Advantages?

• Specialized expertise in the discovery, development, and commercialization of polyclonal antibodies.
• Existing commercial products (Travelan, Protectyn) with established market presence in specific niches.
• Proprietary technology and intellectual property surrounding its hyperimmune product platform.
• Strategic collaborations with governmental research institutions providing access to specialized expertise and funding.
• Diverse clinical pipeline targeting multiple infectious diseases and gut health conditions.

What Does IMRN Do?

Immuron Limited, established in 1994 and headquartered in Carlton, Australia, is a biopharmaceutical company dedicated to the discovery, development, and global commercialization of polyclonal antibodies. The company's operations are strategically divided into two primary segments: Research and Development, and Hyperimmune Products, with a presence across Australia, the United States, and other international markets. Immuron's current commercial offerings include two key products. Travelan, an over-the-counter (OTC) medicine, is designed to reduce the risk of traveler's diarrhea and alleviate symptoms of minor gastrointestinal issues, also functioning as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement specifically formulated to support healthy digestive function and liver health. Beyond its commercialized products, Immuron maintains an active and diverse pipeline. An advanced formulation of Travelan, designated IMM-124E, is currently undergoing Phase III clinical trials. This variant is being developed not only to further mitigate the risk of traveler's diarrhea but also for its potential anti-viral activity, specifically against SARS-CoV-2. Another significant pipeline candidate, IMM-529, is in clinical development, with its primary focus on treating recurrent Clostridium difficile infections, a serious and often challenging medical condition. Immuron also fosters strategic collaborations to expand its research and development capabilities. These include a research agreement with the Naval Medical Research Center, aimed at developing and clinically assessing a therapeutic targeting Campylobacter and ETEC (enterotoxigenic Escherichia coli) infections. Furthermore, the company has a collaboration with the Walter Reed Army Institute of Research, focused on creating an oral therapeutic solution for shigellosis, highlighting its commitment to addressing critical infectious disease challenges.

What Products and Services Does IMRN Offer?

• Discovers, develops, and commercializes polyclonal antibodies for human health.
• Operates in two segments: Research and Development, and Hyperimmune Products.
• Markets Travelan, an over-the-counter medicine for traveler's diarrhea prevention and symptom reduction.
• Offers Protectyn, an immune supplement supporting healthy digestive function and liver health.
• Conducts Phase III clinical trials for IMM-124E, an advanced Travelan formulation with potential anti-viral activity against SARS-CoV-2.
• Develops IMM-529 in clinical trials for treating recurrent Clostridium difficile infections.
• Engages in strategic research collaborations with institutions like the Naval Medical Research Center and Walter Reed Army Institute of Research for infectious disease therapeutics.

How Does IMRN Make Money?

• Generates revenue through the sale of over-the-counter hyperimmune products like Travelan and Protectyn.
• Invests significantly in research and development to advance a pipeline of novel polyclonal antibody therapeutics.
• Seeks regulatory approvals for new drug candidates to expand its commercial product portfolio.
• Engages in strategic collaborations and research agreements, potentially leading to milestone payments or licensing opportunities.
• Aims to commercialize new therapeutics globally, targeting both consumer health and specialized medical markets.

What Industry Does IMRN Operate In?

Immuron Limited operates within the highly specialized and competitive biotechnology industry, specifically focusing on oral immunotherapeutics derived from polyclonal antibodies for gut health and infectious diseases. The global market for digestive health products continues to expand, driven by increasing consumer awareness of gut-brain axis connections and demand for preventative health solutions. Immuron's flagship product, Travelan, positions it within the growing global travel health market, which is experiencing renewed vigor post-pandemic. The company's pipeline, particularly IMM-124E for traveler's diarrhea and anti-viral applications, and IMM-529 for Clostridium difficile, addresses significant unmet medical needs. While the biotechnology sector is characterized by high R&D costs and regulatory hurdles, successful product development can lead to substantial market opportunities. Immuron differentiates itself through its unique polyclonal antibody platform and strategic collaborations with governmental research institutions, aiming to carve out niches in both consumer health and specialized therapeutic areas.

Who Are IMRN's Key Customers?

• International travelers seeking preventative measures for traveler's diarrhea (for Travelan).
• Individuals looking for immune and digestive health support (for Protectyn).
• Healthcare providers and patients seeking treatments for recurrent Clostridium difficile infections (for IMM-529, upon approval).
• Military organizations and public health bodies interested in therapeutics for Campylobacter, ETEC, and Shigellosis (through collaborations).
• Consumers in Australia, the United States, and other international markets.

Immuron Limited has missed Wall Street's EPS estimate in 3 of its last 4 reported quarters — a mixed record worth weighing. Reported results have landed about 2251.4% below estimates on average.

Immuron Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.73 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Immuron Limited stands at -43.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -30.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -54.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -51.4%, the inverse of the P/E and a quick read on earnings relative to price.

Immuron Limited (IMRN) Valuation Context

Valued at $10.5M, IMRN is classified as a micro-cap stock. Relative to its peer group, IMRN's quantitative score of 24/100 is below the peer average of 77/100.

IMRN Revenue & Earnings Trend

In Q4 FY2026, IMRN generated $3.6M in top-line revenue, marking a sequential decrease of 12.9%. The company recorded a net loss of $1.9M, with diluted EPS of $-0.24. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, IMRN averaged $-0.30 in diluted EPS.

Company Profile

Immuron Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Carlton, AU. The company is led by CEO Steven George Lydeamore. IMRN has traded publicly since 2017.

IMRN Financials

IMRN Latest News

IMRN Analyst Consensus

IMRN MoonshotScore

IMRN Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources